D. Western Therapeutics Institute, Inc.

DB:6DW Stock Report

Market Cap: €40.7m

D. Western Therapeutics Institute Past Earnings Performance

Past criteria checks 0/6

D. Western Therapeutics Institute's earnings have been declining at an average annual rate of -52%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 0.4% per year.

Key information

-52.0%

Earnings growth rate

-48.8%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate0.4%
Return on equity-107.9%
Net Margin-236.5%
Next Earnings Update10 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How D. Western Therapeutics Institute makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6DW Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24463-1,0962571,152
30 Jun 24464-1,0852541,157
31 Mar 24442-1,0352561,163
31 Dec 23428-812258930
30 Sep 23452-646263663
30 Jun 23425-566262564
31 Mar 23429-505260507
31 Dec 22448-429255469
30 Sep 22408-273251439
30 Jun 22423-176247363
31 Mar 22434-128242326
31 Dec 21414-148248316
30 Sep 21430-227248394
30 Jun 21405-262261379
31 Mar 21370-274264354
31 Dec 20355-276253350
30 Sep 20369-136232252
30 Jun 20368-98202251
31 Mar 20379-62184247
31 Dec 19580133187249
30 Sep 19538-61208388
30 Jun 19537-248231566
31 Mar 19514-412263683
31 Dec 18292-748268795
30 Sep 18267-798269823
30 Jun 18293-605269753
31 Mar 18279-1,578263675
31 Dec 17254-1,563276603
30 Sep 17239-1,398276459
30 Jun 17151-1,464276338
31 Mar 17126-385266284
31 Dec 16168-253260226
31 Dec 1561-296195143

Quality Earnings: 6DW is currently unprofitable.

Growing Profit Margin: 6DW is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6DW is unprofitable, and losses have increased over the past 5 years at a rate of 52% per year.

Accelerating Growth: Unable to compare 6DW's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6DW is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 6DW has a negative Return on Equity (-107.93%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 11:17
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

D. Western Therapeutics Institute, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution